MACROGENICS INC

MacroGenics lands a $24.5 M milestone from Sanofi after FDA approval of TZIELD®, a breakthrough monoclonal antibody for CLL and NHL, boosting its biotech pipeline and market confidence.

MacroGenics Inc. is navigating a financial rollercoaster amidst promising developments, including a $70 million royalty deal with Sagard and positive clinical trial results for its cancer treatment retifanlimab.

MacroGenics Inc. has entered a strategic partnership with Sagard Healthcare Partners, positioning the biotechnology company for growth and stability in the expanding market for targeted cancer therapies.

MacroGenics Inc. reported strong Q1 2025 financial results, exceeding revenue and EPS expectations, despite market volatility, positioning the biotech firm for future growth.